10.31.23 -- Are KRAS Inhibitors Poised To Cure Cancer?

Development of physically stable, biologically active dry powder formulations of large molecules for inhalation has remained a challenge.

We demonstrate how high-throughput perfusion mimic processes can be achieved in microbioreactors with good consistency among the replicates and with sustained cell viability and protein production.

The successful transition from initial synthesis of an API to a kilogram-scale route requires expert analysis and design, and a balance of economic, regulatory, and time constraints.

Devoting early-phase resources for solid form understanding and screening during a drug’s development life cycle is critical, as doing so can help save time and resources on the path to market.